TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24756515

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.1 mg/kg IV, repeat at 5 minutes if necessary)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg IV, repeat at 5 minutes if necessary)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.1 mg/kg IV)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg IV)
Number of subjects: 273
Study: 22882126

Group type: EXPERIMENTAL
Intervention: Novel complex of lipophilic ingredients (cetyl alcohol, isostearyl isostearate, potassium cetyl phosphate, cetyl behenate, behenic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparable mineral oil-containing vehicle
Number of subjects: 0
Study: 21094360

Group type: EXPERIMENTAL
Intervention: Statin-fenofibrate combinations
Number of subjects: 584784

Group type: COMPARATOR
Intervention: Statins alone
Number of subjects: 584784
Study: 18685046

Group type: EXPERIMENTAL
Intervention: Midgait method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-step method
Number of subjects: 0
Study: 15920040

Group type: COMPARATOR
Intervention: Algorithm 1 (investigator led)
Number of subjects: 4961

Group type: EXPERIMENTAL
Intervention: Algorithm 2 (performed by study subjects)
Number of subjects: 4961

Group type: EXPERIMENTAL
Intervention: Both algorithms
Number of subjects: 4961
Study: 12524668

Group type: EXPERIMENTAL
Intervention: 75 g glucose given to fed subjects
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 75 g glucose given to 4-day-fasted subjects
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 33 g glucose in OGTT for 13-hour-fasted subjects
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 100 g glucose in OGTT for 13-hour-fasted subjects
Number of subjects: 13
Study: 10472349

Group type: EXPERIMENTAL
Intervention: Docetaxel/Irinotecan at dose level 1 (20/25 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Docetaxel/Irinotecan at dose level 2 (20/40 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Docetaxel/Irinotecan at dose level 3 (25/55 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined treatment (Docetaxel/Irinotecan with radiotherapy)
Number of subjects: 12
Study: 8622389

Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg three times daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 81
Study: 2060716

Group type: EXPERIMENTAL
Intervention: High fasting plasma insulin concentration and low 2-h plasma insulin concentration after a glucose load
Number of subjects: 5042

Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance with elevated fasting plasma glucose
Number of subjects: 5042

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance based on 2-h postload glucose
Number of subjects: 5042
Study: 7070890

Group type: EXPERIMENTAL
Intervention: Convectively heated incubator
Number of subjects: 16

Group type: COMPARATOR
Intervention: Open radiant warmer
Number of subjects: 16
Study: 31877631

Group type: EXPERIMENTAL
Intervention: Sucralose ingested
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham-fed sucralose
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 21
Study: 29106034

Group type: EXPERIMENTAL
Intervention: BIP CVC
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard CVC
Number of subjects: 34
Study: 26890014

Group type: EXPERIMENTAL
Intervention: SubQ ADD-ON
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 25027821

Group type: EXPERIMENTAL
Intervention: GnRH agonist protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 60
Study: 22760800

Group type: EXPERIMENTAL
Intervention: Corneal cross-linking procedure
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.1% riboflavin (w/v) eyedrops in 20% dextran solution for 1 month
Number of subjects: 39
Study: 20667082

Group type: EXPERIMENTAL
Intervention: Muscle-strengthening program with load (50 to 70% of 1RM), three times per week for ten weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no new activities during the initial study period)
Number of subjects: 26
Study: 17993041

Group type: EXPERIMENTAL
Intervention: Modafinil 200, 300, or 400 mg once daily for up to 12 weeks
Number of subjects: 1529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 1529
Study: 15598674

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d, n = 25)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg three times daily, n = 27)
Number of subjects: 52
Study: 11388521

Group type: EXPERIMENTAL
Intervention: Low remifentanil (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderate remifentanil (0.15 microg x kg(‐1) x min(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 10
Study: 9241305

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (20 micrograms/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Endometrial resection
Number of subjects: 70
Study: 8427821

Group type: EXPERIMENTAL
Intervention: Topical betamethasone-17-valerate
Number of subjects: 0
Study: 3669078

Group type: EXPERIMENTAL
Intervention: Communication Technique Training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sexual Technique Training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination Treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Attention‐Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: No‐Treatment
Number of subjects: 20
Study: 31043129

Group type: EXPERIMENTAL
Intervention: High-load resistance training (HL-RT, e.g. 70% of 1 repetition-maximum, 1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-load resistance training with partial blood flow restriction (LL-BFR, e.g. 20% 1RM)
Number of subjects: 10
Study: 31892724

Group type: EXPERIMENTAL
Intervention: Training in chopstick use with the non-dominant (left) hand for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study: 28238522

Group type: EXPERIMENTAL
Intervention: Standard care plus endovascular treatment
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 77
Study: 24807875

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 68
Study: 23622053

Group type: EXPERIMENTAL
Intervention: SF6D
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: EQ5D
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: ODI
Number of subjects: 172
Study: 21813857

Group type: EXPERIMENTAL
Intervention: DENV vaccine (34 subjects; four received 1/10th dose)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control vaccine (17 subjects; dose 1: live varicella; dose 2: Haemophilus influenzae type b)
Number of subjects: 51
Study: 19356272

Group type: EXPERIMENTAL
Intervention: Regular-energy orangeade with large sips (20 g/sip)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Regular-energy orangeade with small sips (5 g/sip)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: No-energy orangeade with large sips (20 g/sip)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: No-energy orangeade with small sips (5 g/sip)
Number of subjects: 53
Study: 16422734

Group type: EXPERIMENTAL
Intervention: Nutritional support algorithm
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard feeding practices (control)
Number of subjects: 42
Study: 15541408

Group type: EXPERIMENTAL
Intervention: Tubal sterilization (TS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (barrier method)
Number of subjects: 36
Study: 11930720

Group type: EXPERIMENTAL
Intervention: 0.8 mm excessive crown contour
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 mm excessive crown contour
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.2 mm excessive crown contour
Number of subjects: 12
Study: 8995749

Group type: EXPERIMENTAL
Intervention: 1 alpha (OH)‐vitamin D2, 4 micrograms/day or 4 micrograms thrice weekly, adjusted over 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 alpha (OH)‐vitamin D2
Number of subjects: 24
Study: 8431571

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diazemuls
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alcohol-propylene glycol (APG)
Number of subjects: 30
Study: 3680575

Group type: EXPERIMENTAL
Intervention: Microencapsulated KCl capsule preparation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Wax-matrix formulation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: New microencapsulated KCl tablet preparation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All treatments (including placebo)
Number of subjects: 16
Study: 29343280

Group type: EXPERIMENTAL
Intervention: Pregabalin plus evidence-based advice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo plus evidence-based advice
Number of subjects: 30
Study: 27143690

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg weekly)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Temozolomide (standard chemo‐radiotherapy)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Phosphorylation of mTORSer2448 in tumor tissue
Number of subjects: 257
Study: 27004344

Group type: EXPERIMENTAL
Intervention: Closed lateral internal anal sphincterotomy (CLIAS) via von‐greaves knife
Number of subjects: 94

Group type: COMPARATOR
Intervention: Open internal anal sphincterotomy (OIAS) (Park's procedure)
Number of subjects: 94
Study: 24078509

Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Number of subjects: 43

Group type: COMPARATOR
Intervention: No fibrin glue (Control)
Number of subjects: 43
Study: 21360491

Group type: EXPERIMENTAL
Intervention: Rituximab (2 × 500 mg intravenously)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 18165599

Group type: EXPERIMENTAL
Intervention: Ropivacaine 90 mg (9 mL), morphine 4 mg (10 mL), and ketorolac 30 mg (1 mL) (total volume 20 mL)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline (20 mL)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: IV ketorolac 30 mg (1 mL)
Number of subjects: 51

Group type: COMPARATOR
Intervention: IV saline (1 mL)
Number of subjects: 51
Study: 17126780

Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 3501

Group type: COMPARATOR
Intervention: No postoperative epidural analgesia (Control)
Number of subjects: 3501
Study: 12948794

Group type: EXPERIMENTAL
Intervention: Carbocaine (10 mg/ml)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Isotonic saline (0.9%)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Jaw gape of 14 mm
Number of subjects: 11
Study: 10970994

Group type: EXPERIMENTAL
Intervention: Enzymatically interesterified butter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Native butter
Number of subjects: 0
Study: 7521662

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) with high-dose melphalan, and additional treatments including fractionated total body irradiation, hemi-body irradiation, and high-dose etoposide.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 30
Study: 2511684

Group type: EXPERIMENTAL
Intervention: 5 x 2.5 mg isosorbide dinitrate (ISDN)
Number of subjects: 608

Group type: COMPARATOR
Intervention: 5 x 40 mg isosorbide dinitrate (ISDN)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Low-dose ISDN
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: High-dose ISDN
Number of subjects: 608
Study: 128287

Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella trivalent vaccine
Number of subjects: 1481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1481
Study: 30901529

Group type: EXPERIMENTAL
Intervention: Yoga intervention for 8 weeks
Number of subjects: 27
Study: 28356484

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 92

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study: 26520396

Group type: EXPERIMENTAL
Intervention: 150 μg corifollitropin alfa
Number of subjects: 694
Study: 24992752

Group type: EXPERIMENTAL
Intervention: Chinese herbs
Number of subjects: 433

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 433
Study: 23011563

Group type: COMPARATOR
Intervention: Toy (group 2)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Animated cartoon (group 3)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (group 1)
Number of subjects: 130
Study: 19606690

Group type: EXPERIMENTAL
Intervention: Bioenterics Intragastric Balloon (BIB)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (conservative treatment)
Number of subjects: 21
Study: 17882847

Group type: EXPERIMENTAL
Intervention: Supported by a clinician and an information analyst in obtaining and analysing their own data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupported
Number of subjects: 0
Study: 14692015

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Yoga Stretching (Hatha)
Number of subjects: 40
Study: 12137238

Group type: EXPERIMENTAL
Intervention: El Paso CATCH
Number of subjects: 24
Study: 9819584

Group type: EXPERIMENTAL
Intervention: Human Error Identification techniques (specifically SHERPA)
Number of subjects: 0
Study: 7568638

Group type: EXPERIMENTAL
Intervention: Repeated trials of the same erotic stimulus
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: A series of varying erotic stimuli
Number of subjects: 62
Study: 1663200

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 0
Study: 7020890

Group type: EXPERIMENTAL
Intervention: Carbonated lidocaine 1.73%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine hydrochloride 2.0%
Number of subjects: 20
Study: 29899050

Group type: EXPERIMENTAL
Intervention: Exercise programme (60 min, 3 days per week throughout pregnancy)
Number of subjects: 124
Study: 25807517

Group type: EXPERIMENTAL
Intervention: Sprint Interval Cycling (SIT)
Number of subjects: 25
Study: 23604689

Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg annually)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 21476064

Group type: EXPERIMENTAL
Intervention: Glimepiride (2 mg single oral dose)
Number of subjects: 177
Study: 19584487

Group type: EXPERIMENTAL
Intervention: Clofibrate with phototherapy
Number of subjects: 68
Study: 17374042

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Coping Skills Therapy (CBCST)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 15338385

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (stationary biking 30 min five times weekly)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Progressive relaxation training (45 min three times per week)
Number of subjects: 72
Study: 11332146

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, 5‐fluorouracil (5‐FU), leucovorin, and interferon‐alpha 2b (PFL‐IFN) followed by concomitant chemoradiation with 5‐FU, hydroxyurea, and total radiotherapy dose of 7000 cGy (FHX)
Number of subjects: 32
Study: 9554570

Group type: EXPERIMENTAL
Intervention: Intermittent calcitriol (1,25D) therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Daily 1,25D therapy
Number of subjects: 16
Study: 8017327

Group type: EXPERIMENTAL
Intervention: Magnesium aspartate-HCl (20 mmol Mg/d)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 2472596

Group type: COMPARATOR
Intervention: Oral iron therapy (10-day trial)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Oral iron therapy (3 months)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Anemic infants
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control infants and nonanemic iron-deficient infants
Number of subjects: 196
Study: 30875390

Group type: EXPERIMENTAL
Intervention: Etelcalcetide 5 mg intravenously three times weekly (TIW) after hemodialysis, with potential dose increases of 2.5 or 5 mg at 4-week intervals to a maximum dose of 15 mg TIW.
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Cinacalcet (active control).
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Placebo (control).
Number of subjects: 3025
Study: 28508114

Group type: EXPERIMENTAL
Intervention: L-menthol mouthwash
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 8
Study: 25603851

Group type: EXPERIMENTAL
Intervention: Sodium Phosphate Tablets (SPT)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Polyethylene Glycol with Ascorbic Acid (PEGA)
Number of subjects: 189
Study: 23612519

Group type: EXPERIMENTAL
Intervention: Home telemedicine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional hospital admission
Number of subjects: 44
Study: 20458210

Group type: EXPERIMENTAL
Intervention: Bevacizumab alone (Arm A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus docetaxel (Arm B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 32
Study: 18302787

Group type: EXPERIMENTAL
Intervention: Individualised exercise and nutrition program (six months duration, commencing within 14 days post-surgery)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 460
Study: 17151965

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Volume-controlled ventilation
Number of subjects: 50
Study: 14559383

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 1006
Study: 10710555

Group type: EXPERIMENTAL
Intervention: Insulin infusion (50 mU. kg(‐1). h(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-dose ANP infusion (0.3 pmol. kg(‐1). h(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose ANP infusion (2 microg/min)
Number of subjects: 8
Study: 9181268

Group type: EXPERIMENTAL
Intervention: Mibefradil (100 mg daily for 12 weeks)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Diltiazem CD (360 mg daily for 12 weeks)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Mibefradil or Diltiazem CD during withdrawal period
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo during withdrawal period
Number of subjects: 201
Study: 8474278

Group type: EXPERIMENTAL
Intervention: Acarbose (3 x 50 mg/day for 1 month, then 3 x 100 mg/day for 2 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 4078054

Group type: EXPERIMENTAL
Intervention: Povidone-iodine-impregnated polyethylene oxide gel (PVPI-POG) dressing
Number of subjects: 45

Group type: COMPARATOR
Intervention: Polyethylene oxide gel (POG) dressing
Number of subjects: 45
Study: 30153194

Group type: EXPERIMENTAL
Intervention: Low-volume group performing one set per exercise per training session (n = 11)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Moderate-volume group performing three sets per exercise per training session (n = 12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-volume group performing five sets per exercise per training session (n = 11)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-volume group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Moderate-volume group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-volume group
Number of subjects: 34
Study: 29310444

Group type: EXPERIMENTAL
Intervention: Galcanezumab 5 mg
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Galcanezumab 50 mg
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Galcanezumab 300 mg
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 26933148

Group type: EXPERIMENTAL
Intervention: Heart Rate Reserve (HRR) method
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Percent of 220-age method
Number of subjects: 14

Group type: COMPARATOR
Intervention: VO2peak
Number of subjects: 14
Study: 25204768

Group type: EXPERIMENTAL
Intervention: Self-directed, multicomponent exercise program
Number of subjects: 152
Study: 22092973

Group type: EXPERIMENTAL
Intervention: DBBM + AB supplemented with autogenous bone cells
Number of subjects: 20

Group type: COMPARATOR
Intervention: DBBM + AB alone
Number of subjects: 20
Study: 19590158

Group type: EXPERIMENTAL
Intervention: Inhalation of thermal water (TW) for 2 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal saline inhalation
Number of subjects: 13
Study: 17403741

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing sealant (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant with high fluoride release (Group 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional sealant without fluoride (Group 1)
Number of subjects: 45
Study: 16327030

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO, 6% w/v)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CHO+VC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC, 0.15% w/v)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 6
Study: 11943036

Group type: EXPERIMENTAL
Intervention: Oral care (tooth brushing after each meal, swabbing with povidone iodine, professional care once a week)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Oral care
Number of subjects: 417

Group type: COMPARATOR
Intervention: No oral care
Number of subjects: 417
Study: 9784543

Group type: EXPERIMENTAL
Intervention: C3b/c levels
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: C3-CRP levels
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Complement activation products
Number of subjects: 52
Study: 7664863

Group type: EXPERIMENTAL
Intervention: Inhaled platelet‐activating factor (PAF) 225 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lyso‐PAF 225 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline bronchial challenge
Number of subjects: 8